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Abstract: 
In respiratory medicine there is a need for clinical biomarkers for diagnosis, prognosis and 
assessment of response to therapy. Non-coding RNA is expressed in all human cells: two 
major classes, ncRNA and microRNA, are detectable extracellularly in the circulation and 
other biofluids. Altered ncRNA expression is associated with lung disease; collectively this 
indicates that ncRNA represents a potential biomarker class. This article presents and 
compares existing platforms for detection and quantification of ncRNA, specifically 
hybridization, qRT-PCR and RNA sequencing, and outlines methods for data interpretation 
and normalization. Each approach has merits and shortcomings, which can affect the choice 
of method when embarking on a biomarker study. Biomarker properties and pre-analytical 
considerations for ncRNA profiling are also presented. Since a variety of profiling 
approaches are available, careful study and experimental design are important. Finally 
challenges and goals for reliable, standardized high-throughput ncRNA profiling in biofluids 
as lung disease biomarkers are reviewed.  
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1. Introduction: 
Three major aspects of clinical medicine that are central to all human diseases are accurate 
diagnosis, prognosis and assessment of response to therapy. Reliable clinical biomarkers that 
facilitate these processes can greatly enhance patient care. As it is usually not possible to 
detect early intrapulmonary changes that occur during the establishment of chronic 
inflammatory lung diseases, the search for surrogate markers of lung disease has been 
ongoing for many years. Circulating RNA, and in particular non-coding RNA, represents a 
relatively recently discovered biomarker class that has potential in this field. This article will 
review the field of non-coding RNA in chronic inflammatory lung disease and present the 
current high-throughput methodologies that can be used for the discovery of non-coding 
RNA biomarkers of lung disease. 
 
2. Non-coding RNA – an introduction 
The human genome encodes a vast amount of non-coding RNA; only ~1.2% of the genome is 
protein-coding, yet much of it is transcribed 1. The Encyclopaedia of DNA Elements 
(ENCODE) consortium has recently reported that up to 75% of the human genome is 
transcribed 2. Thus many of these transcripts are non-coding but do have important roles 
nonetheless. Non-coding RNA (ncRNA) is a class of endogenous, non-protein coding RNA 
transcripts with very diverse, yet essential roles in almost all cellular processes. Several types 
of ncRNA transcripts exist, and are broadly characterised based on size; long ncRNA 
(lncRNA) over 200 nucleotides (nt) in length; and short ncRNA, less than 200 nt.  
2.1 microRNA 
Of the small ncRNA, microRNAs (miRNA) are the most notable and most extensively 
studied. miRNAs are 21-24 nucleotide duplex RNAs involved in the translational regulation 
of gene expression 3. Although the term ‘microRNA’ was first coined in 2001, the first 
miRNA, lin-4, was discovered eight years earlier in the nematode Caenorhabditis elegans 4. 
Having been initially discovered to have importance in developmental biology, interest in 
these small RNAs has dramatically increased since this time as they have been found to have 
significant roles in almost all biological processes. Expression levels of miRNAs vary greatly 
between cells and tissues, and indeed aberrant levels of miRNA are associated with many 
diseases in humans. miRNA generally regulate gene expression post-transcriptionally by 
 
 
binding to the 3’UTR of a target messenger RNA (mRNA). Although most miRNA studies 
have largely focused on miRNA-mRNA interactions in the 3’UTR of target mRNA, these 
interactions can occur in the 5’UTR and coding sequence (CDS) 5,6. An interesting aspect of 
miRNA regulation of mRNA translation lies in the fact that full complementarity between 
miRNA and target mRNA is not required. In fact, only partial complementarity is required 
and a 2-8 nucleotide (nt) ‘seed region’ is thought to be crucial in the selection of targets by 
miRNA 7,8. Binding to miRNA responsive elements (MREs) in target mRNA appears to 
occur through this seed region. Messenger RNAs typically have many different MREs and 
can therefore be regulated by more than one miRNA.  
2.2 Long non-coding RNA 
Long non-coding RNAs (lncRNAs) are an emerging class of ncRNA. Unlike miRNA whose 
functions are generally mediated through binding with target mRNAs and affecting 
translation; lncRNAs are implicated in the regulation of gene expression at almost every 
level. Although their precise mechanisms of action are relatively unknown, common 
mechanistic themes are emerging. They have the ability to affect gene expression through a 
spectrum of interactions with proteins, RNA and DNA. With their capacity to act both in cis 
and in trans, they can guide epigenetic modifier complexes or transcription factors to 
particular genomic sites. These lncRNAs have been implicated in a variety of cellular 
processes, including genomic imprinting, chromatin modification and the regulation of 
cellular cycle.  
 
3. Non-coding RNA in respiratory disease 
Much recent evidence demonstrates that both miRNA and lncRNA are required to regulate 
lung development and maintain homeostasis 9,10. During both murine and human lung 
development, widespread changes in miRNA expression have been observed 11. For example, 
DICER, a key enzyme required for miRNA biogenesis, has been shown to be essential for 
proper lung epithelial morphogenesis; Dicer knockout mice, who have disrupted miRNA 
processing, display a lethal phenotype as a result of impaired lung growth 12. It is also known 
that lncRNA expression patterns are altered in pathological states, such as lung cancer, lung 
inflammation and various lung diseases.  
  
 
 
3.1 Altered miRNA expression associated with lung disease  
Many ncRNA expression and function studies in the lung have been performed in the 
context of lung cancer and the current understanding of ncRNA as lung cancer biomarkers 
were recently reviewed 13. Here we will provide a brief overview of miRNA studies that 
have been performed in a selection of chronic inflammatory lung diseases.  
The World Health Organisation predicts Chronic obstructive pulmonary disease (COPD) to 
become the third leading cause of death worldwide by 2030 14. COPD is a debilitating lung 
disorder which is characterised by progressive airflow obstruction that is not fully reversible. 
It is associated with an enhanced inflammatory response to gasses and noxious particles, in 
particular from cigarette smoke, and is a leading cause of morbidity 15. COPD is a 
heterogeneous disease with the main clinical manifestations being various combinations of 
chronic bronchitis and emphysema. It is currently incurable, although smoking cessation and 
symptomatic treatment can delay disease progression. Akbas and colleagues 16 were the first 
to screen COPD serum for miRNA-based biomarkers and found five miRNAs (miR-20a, 
miR-28-3p, miR-34c-5p, miR-100 and miR-7) to be significantly dysregulated.  Another 
study which compared miRNA expression in plasma of COPD patients compared with 
healthy smokers, found nine differentially expressed miRNAs in COPD (miR-29b, miR-483-
5p, miR-152, miR-629, miR-26b, miR-101, miR-106b, miR-532-5p and miR-133b) 17.  The 
data on plasma levels of miR-106b in COPD ex-smokers led the authors to suggest that 
plasma miR-106b levels may reflect persistent and systemic changes even after smoking 
cessation. Another recent study has suggested serum miR-21 and miR-181a and their ratio as 
potential biomarkers for predicting COPD development in heavy asymptomatic smokers 18. 
Unlike COPD, asthma is a chronic inflammatory airways disease that is characterised by 
reversible airflow obstruction. However in a significant minority of asthmatics the airflow 
obstruction is not reversible and in severe cases poor responses to steroid and beta agonist 
therapies can result in potentially fatal attacks 19,20. Hence there is an unmet clinical 
requirement for biomarkers of asthma, and in particular the more severe phenotypes. Very 
few studies have investigated cell-free miRNA expression in serum and plasma of asthmatics, 
and most of the focus has been on their expression within circulating T cells 21. One of these 
studies has identified differential  expression of miR-1248, miR-26a, Let-7a, and Let-7d in 
serum of asthmatic patients compared to controls 22. Some interesting work has begun on the 
use of exhaled breath condensate (EBC) as a noninvasive convenient representation of the 
 
 
airway lining fluid. Interestingly miRNAs are detectable in these samples 23 and  miRNAs 
such as miR-1248, miR-155 and let-7a have been found to be differentially expressed in EBC 
from asthmatics versus healthy controls 24. miR-570-3p has been shown to be induced in 
TNFα-treated airway epithelial cells and its levels in EBC inversely correlate with FEV1% in 
asthmatics 25.  
Cystic fibrosis (CF) is a lethal multi-system autosomal recessive disease affecting many 
organs. It is characterised by mutations in the cystic fibrosis transmembrane conductance 
regulator (CFTR) gene. A deletion of a phenylalanine residue at position 508 of the CFTR 
protein (F508del) is the most frequent mutation, accounting for approximately 70% of the 
alleles in CF world-wide, although over 1,900 mutations have been identified to-date 26. 
We have been the first to examine miRNA expression in people with CF 27. The expression 
levels of several miRNA were found to be altered in the bronchial epithelium of people 
with versus without CF. For example, miR-126 was significantly down-regulated in the CF 
lung. Down-regulation of this miRNA was associated with an up-regulation of target of 
Myb1 (TOM1), a negative regulator of IL-1β, TLR2 and TLR4 induced signaling, and this 
mRNA was shown to be directly targeted by miR-126. Various groups have examined the 
role of miRNAs in controlling CFTR expression with various miRNAs being demonstrated 
to regulate CFTR 28–33. These studies have found some differences in the miRNAs reported 
to regulate CFTR but this is most likely due to different experimental situations, such as 
different cell types and responses to different stimuli such as cigarette smoke. Such 
miRNAs include miRs -138 32, -223 33, -224 34, -509-3p 28, -4921 28, however miRs -101, -
145 and-494 have been replicated in more than one of these studies 29–31,33,35. For example, 
we have demonstrated that miR-145, miR-223 and miR-494 are up-regulated in CF 
bronchial epithelial cells and cell lines, are inversely correlated with CFTR levels and 
directly target CFTR mRNA 33. Their expression also correlated with p.Phe508del 
mutation and colonisation with Ps. aeruginosa. Other recent studies have postulated that 
miRNA may be useful in the therapy of CF 36,37. For example, Kumar et al. have identified 
that a miR-16 mimic can rescue F508del-CFTR protein function in primary cultures and 
airway cell lines 37. Several studies have also examined the roles of miRNA in 
inflammation in CF. Ps. aeruginosa infection induces the production of pro-inflammatory 
cytokines such as IL-8 in the CF airway epithelium. Fabbri and colleagues 38 have found a 
decrease in miR-93 levels in CF bronchial epithelial cells during infection with this major 
CF pathogen and that this miRNA directly targets IL-8 mRNA. We reported similar 
 
 
findings for miR-17 39 whist  Zhang et al. 40 have shown that high levels of miR-199a-5p in 
human and murine CF macrophages and murine CF lungs leads to increased TLR4 
signaling.  
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive disease of the lung interstitium, 
usually occurring in middle-aged and elderly adults. It is characterised by epithelial cell 
damage, fibroblast proliferation and exaggerated accumulation of extracellular matrix within 
the lung parenchyma. Let-7d was the first miRNA demonstrated to be involved in the 
pathogenesis of IPF, reported in 2010 41. Since then a number of studies have examined roles 
of miRNA in the pathogenesis of this condition 42–45. Yang et al. 46 reported 47 differentially 
expressed miRNAs in the serum of IPF patients compared to healthy controls. They validated 
six of these (miR-21, miR-199a-5p and miR-200c are increased whereas miR-31, let-7a, and 
let-7d are under-expressed) in an independent cohort, thus demonstrating the potential of 
serum miRNA as biomarkers of IPF. Another recent study demonstrated that altered serum 
levels of miR-21, miR-155 and miR-101-3p were associated with forced vital capacity (FVC) 
and radiological features in IPF 47. 
3.2 Lung disease lncRNA expression patterns  
lncRNAs have been less well characterised than miRNA in COPD, asthma and CF and there 
is just one report to-date on the expression and function of lncRNA in IPF 45. In COPD the 
most exciting development in this area relates to a recently discovered novel lncRNA, termed 
the smoke and cancer-associated lncRNA-1 (SCAL1). As its name hints, this lncRNA is 
elevated in numerous lung cancer cells lines, upregulated in vitro by cigarette smoke extract 
48 and is also elevated in the airway epithelia of cigarette smokers versus non-smokers 49. In 
another report genome-wide expression analysis of lncRNA in the lung tissue of non-smokers 
without COPD, and smokers with and without COPD led to the discovery that various 
lncRNAs are altered in COPD patients compared to smokers without COPD 50. As in other 
chronic inflammatory lung diseases, lncRNA have also been under-explored in the 
pathophysiology of asthma. Perry et al 51 have detected altered expression of numerous 
lncRNAs in corticosteroid treated airway smooth muscle cells; key cells in the pathogenesis 
of asthma. Interestingly, they propose that four of these (RP11-46A10.4, LINC00883, 
BCYRN1, and LINC00882) act as miRNA ‘sponges’ for miR-150, miR−371-5p, miR−940, 
and miR−1207-5p, respectively. Widespread changes in the expression of lncRNAs have also 
been observed in circulating CD8+ T cells from patients with severe asthma 21. Whilst very 
 
 
little is known about the role of lncRNA in cystic fibrosis a recent study of ours has 
demonstrated an altered lncRNA expression profile in the bronchial epithelium of adults with 
CF when compared to non-CF controls 52. 
4. Platforms for detection and quantification of non-coding RNA expression 
Traditional methods for detection of non-coding RNA include in-situ hybridisation and 
northern blotting, and these are still very much applicable to the detection of ncRNA, 
however this review will focus on newer, higher throughput approaches (Figure 1. Steps in 
high-throughput profiling of ncRNA expression and some important considerations). 
Profiling of non-coding RNA, like mRNA, can essentially be categorised into three 
approaches, depending on the technology used; hybridisation, qPCR and RNA sequencing 
(RNA-seq). Although each method has its own benefits they also have significant limitations. 
Such limitations include the number of RNAs that can be analysed simultaneously; the 
source, quality and amount of RNA required; sensitivity and specificity of detection; and the 
requirement for prior knowledge of targets 53,54. In comparison to mRNA species, primer and 
probe design for quantification of ncRNA abundance is difficult. The small size of miRNA, 
presence of isomiRs and sequence similarity between families, as well as lack of 
polyadenylation contribute to the difficulty of expression profiling of these RNAs. Previously 
inadequate annotation was a limiting factor in the design of primers and probes for miRNA 
detection but this has been significantly improved with the growth of miRBase; the 
comprehensive public repository of miRNA sequences 55. Therefore, there has been a 
considerable increase in the choice of products available for detection of these small 
miRNAs. On the other hand, inadequate annotation is probably the greatest current limitation 
of lncRNA assay design, although this is rapidly improving. Detection of lncRNAs can be 
quite difficult, but this varies from transcript-to-transcript. lncRNAs are often found in 
intergenic regions or ‘gene deserts’ with high GC content, many are not polyadenylated, and 
some are antisense to protein coding genes with lower abundance, meaning strand specific 
PCR amplification is required 56.  
4.1 Hybridisation 
Microarrays are the classical example of a hybridisation based approach to ncRNA 
expression analysis. Microarrays utilise the hybridisation of fluorescently tagged ncRNAs (be 
they miRNA or lncRNA) within a sample to glass printed DNA-based capture probes, 
followed by laser scanning of the slide and quantification of fluorescence associated with 
 
 
each spot. A limitation of this method when examining miRNAs is that their small size means 
widely varying melting temperatures (Tm) of each probe can reduce specificity and/or 
sensitivity, especially for low GC content miRNAs 57.  This issue may be overcome through 
the use of Locked Nucleic Acid (LNA) probes, which contain a synthetic DNA/RNA 
analogue which significantly increases the Tm 58. A large number of microarray platforms 
exist, with differences ranging from probe design and labelling methods, to surface chemistry 
and printing technology 59. A major advantage of microarrays is their reproducibility, 
flexibility and ability to simultaneously detect a large number of ncRNAs. However, they do 
suffer from a limited linear range of quantification (typically over 2-3 logs), imperfect 
sensitivity; particularly for highly similar miRNA sequences, and they cannot be used for 
absolute quantification. The NanoString nCounter technology has been a recent innovation in 
RNA profiling based on hybridisation 60. This technology involves the use of colour-coded 
tags coupled to the reporter probe, and through permutations in the order of fluorochromes a 
molecular barcode is created for each ncRNA. This technology has been adapted for miRNAs 
and, more recently lncRNAs. However, this system has limitations when low-abundance 
RNA samples are used, such as serum/plasma. There is a requirement for 100 ng of 
concentrated RNA (33 ng/μl) and thus an additional concentration step may be required, 
and/or larger volumes of serum are recommended (400 μl or more). 
4.2 qRT-PCR 
qRT-PCR is probably the easiest method for detection of ncRNA, and most laboratories have 
the equipment/hardware for performing PCR, especially those already examining mRNA 
expression. Analysis of ncRNA expression can be performed using either SYBR® Green or 
TaqMan® approaches, and various vendors offer pre-designed assays for miRNA and 
lncRNA.  
Due to their small nature, miRNAs are difficult to detect by PCR, however various 
approaches have overcome this difficulty. TaqMan® miRNA assays contain a unique stem-
loop RT primer to allow for reverse transcription of only mature miRNAs with high 
specificity. Reverse transcription using these primers results in a mature miRNA/primer 
chimera which extends the 3’ end of the miRNA, creating a longer product for specific 
probes and primers to anneal during PCR 61. Life Technologies have been the leader in the 
field of miRNA qPCR profiling, with microfluidic based TaqMan® Low Density Array 
(TLDA) cards, and more recently the adaptation of the nanofluidic based OpenArray® (OA) 
 
 
system for miRNA profiling. Advances in nano- and micro-fluidic engineering has enabled a 
larger number of reactions to be performed in smaller reaction volumes 62. Essentially, these 
fluidic platforms allow for multiplexing of TaqMan® miRNA assays. TLDA enables the 
profiling of 384 miRNAs per card and two cards (Cards A & B) cover 754 of the Sanger 
miRBase v14 annotated miRNAs. Card A allows for the profiling of well characterised 
miRNAs, with Card B containing assays for more recently discovered miRNAs. Therefore, 
this technology has been medium-throughput at best, but Life Technologies’ OA system is a 
more recently devised high-throughput approach. OA allows for profiling of 754 miRNAs 
per sample, with the ability to profile up to 12 samples in a single run.  
Other manufacturers have exploited the SYBR® Green route for miRNA profiling. The 
Qiagen SYBR® Green based miScript PCR system focuses on polyadenylation of small 
RNAs (including pre-miRNAs and other RNAs), and subsequent reverse transcription of 
mature miRNAs using an oligo-dT primer with a common tag sequence. The specificity is 
controlled by the proprietary dual buffer system used by the RT step 61. PCR amplification 
proceeds with a universal reverse primer (utilising the tag sequence site) and a miRNA-
specific forward primer, followed by SYBR® Green chemistry based detection and 
quantification 56. The Exiqon based miRCURY LNA™ PCR is also a SYBR® Green based 
approach, which uses polyadenylation of small RNAs followed by RT. However, specificity 
for miRNA amplification is achieved using LNA-enhanced forward and reverse primers. 
Both of these SYBR-based approaches are in essence, medium-throughput, being 384-well 
formats or lower.  
As already discussed, there are some challenges posed to the expression profiling of lncRNA, 
when compared to mRNA. However, many manufacturers are allocating resources to 
improve the large scale quantification of lncRNA. For example, Life Technologies now have 
pre-designed TaqMan® assays for over 15,000 human ncRNAs, however these are currently 
only provided in individual assay format, and there is no option for multiplexing of yet. 
WaferGen have introduced a PCR array for lncRNA based on its SmartChip panel 
technology which contain over 1,700 triplicate, predispensed PCR assays that have been 
rigorously validated. Qiagen have extrapolated their RT2 PCR array platform to include 100-
well ring disc or 96 and 384 well plate formats for the quantification of multiple lncRNAs 
within a sample, but with a maximum of 84 lncRNAs detected per sample. Similarly, 
Systems Biosciences have developed 96-well plate PCR array formats for quantification of 
various well characterised lncRNAs. Clearly, high-throughput analysis of lncRNA expression 
 
 
by qRT-PCR is lagging behind that of mRNA or miRNA, but is likely to improve with 
developments in annotation and characterisation of lncRNAs. 
4.3 Next-generation sequencing/RNA-seq 
RNA-seq is a relatively recent approach to transcriptomics and relies on Next-Generation 
Sequencing (NGS) technologies, which are excellently reviewed elsewhere 63,64. The major 
advantage of NGS is that prior knowledge of target ncRNA is not required, nor are specific 
primers or probes needed. Several manufacturers offer high-throughput NGS platforms, with 
varying technologies. RNA-seq offers many advantages over microarray approaches and is 
currently the best platform for both miRNA and lncRNA discovery. With single nucleotide 
resolution, RNA-seq works on a genome-wide scale, allowing for the precise identiﬁcation of 
and quantification of RNAs. Compared with probe-based microarrays, RNA-seq has a much 
larger dynamic range (potentially infinite, depending on sufficient sequencing depth) and 
offers the ability to detect transcripts with very low expression 65. However, this approach 
does suffer from some limitations. It is relatively expensive and the resources required for 
downstream data analysis can be quite significant. Nonetheless, RNA-seq permits unbiased 
global ncRNA detection and expression quantiﬁcation. It is important to decide whether to 
use total or poly-adenylated RNA before beginning RNA-seq, as the presence of ribosomal 
and transfer RNA can severely reduce cDNA library diversity during ampliﬁcation 65. Some 
studies66,67  have suggested that depletion of ribosomal RNA may be superior in producing 
reliable expression data, as opposed to using polyadenylated RNA, given the high percentage 
of RNA transcripts that are not poly-adenylated (estimated at 40% 68). The sequencing 
approach also depends on the nature of the RNA species examined; i.e. whether miRNA or 
lncRNA are profiled. Generally, small RNAs such as miRNAs can be directly sequenced by 
adapter ligation, but larger RNAs require fragmentation to become compatible with most 
RNA-seq technologies 63. 
4.4 Comparisons between platforms 
Generally speaking, microarray technology is a very cost effective means of high throughput 
profiling of ncRNA expression. In addition, when comparing to low sequencing coverage 
RNA-seq, arrays may be superior in terms of having lower technical variation and better 
detection sensitivity for low-abundance transcripts which is a prominent feature of lncRNAs 
69. RNA-seq with sufficient coverage and depth has the advantage of de novo ncRNA 
discovery, however as some ncRNA are in low abundance, higher costs of RNA-seq may be 
 
 
envisaged due to higher depth of sequencing required to accurately detect these transcripts. 
Nevertheless, RNA-seq costs have reduced significantly in recent years and further 
reductions in cost and improvements in technology will facilitate more detailed RNA-seq 
studies. RNA-seq and microarray have the advantage over RT-PCR in terms of throughput, 
especially when examining lncRNA expression, however RT-PCR is still seen as a ‘gold-
standard’ in expression studies, and is particularly useful in the validation of high-throughput 
data. Studies comparing the performance of these different platforms with respect to analysis 
of non-coding RNA expression are lacking, particularly for the more under-studied lncRNA. 
One recent study that comprehensively compared several platforms for miRNA expression 
profiling has concluded that each method has its strengths and weaknesses, which should help 
guide informed selection of the correct platform for particular study goals 70, and this may 
also be applicable to lncRNA profiling. In addition, the use of in situ hybridisation (ISH) 
techniques must also be mentioned. This highly sensitive approach is based upon the 
detection of specific RNAs via hybridisation of a complementary (probe) strand to the 
sequence of interest in tissue or cell preparations. The ISH method, usually coupled with a 
fluorescent (FISH) or chromogenic (CISH) readout allows for the analysis at a single cell or 
subcellular level. Although this currently is a semi-quantitative and low throughput method, it 
is powerful in the fact that it allows for localisation of signals to specific cell-types. 
Interestingly, this situation is improving, particularly since the introduction of LNAs. For 
example, significant progress has been made quite recently, allowing for higher throughput 
when Battich and colleagues combined branched DNA technology with automated liquid 
handling, high-content imaging and quantitative image analysis and showed that this allows 
highly reproducible quantification of transcript abundance in thousands of single cells at 
single-molecule resolution 71. 
4.5 Data interpretation and normalisation 
Whatever profiling technology is utilised, particular attention must be placed on 
interpretation of biological meaning of the large amounts of data that ncRNA profiling 
generates. Raw data must be processed and a quality assessment performed. Special 
consideration must be given to data normalisation, and this can be difficult for samples with 
low RNA concentrations such as serum/plasma. This step is crucial in order to remove 
variation between samples which is not due to biological conditions studied 72 in order to 
improve detection of true biological differences. For qRT-PCR data, the most common 
approach is the use of endogenous control RNAs that are found to be relatively invariant 
 
 
between samples in a given experiment 73. A second strategy involves a global measure of 
expression and has been used in large-scale qRT-PCR and, particularly microarray profiling 
datasets, where large numbers of RNAs are profiled simultaneously.  Using this approach one 
assumes that although individual RNA levels may vary, the overall pattern of expression is 
expected to be invariable. Variations such as global geometric mean expression, Loess, 
quantile normalisation and others have been utilised in this approach, and this approach 
appears to perform better than when using endogenous controls 74,75. Another approach uses 
synthetic control RNAs, generally from a different species, which are spiked in at a known 
concentration into each RNA sample. This provides excellent quality control for various 
aspects of technical variation, for example reverse transcription for RT-PCR profiling, but it 
requires that assays for the spiked in controls be available on the platform used, which is not 
always the case. However, for samples with low RNA concentrations where variable amounts 
of RNA are used for profiling the spike-in method is unreliable, and therefore better used as 
an extraction efficiency tool 61. Normalisation methods for RNA-seq data are less well 
developed. Many existing normalisation methods are insufficient at removing RNA 
composition bias and other unwanted complex technical effects, and efforts are underway to 
achieve an improvement in RNA-seq normalisation 76,77. 
 
5. Properties of biomarkers 
Biomarkers are important diagnostic tools reflecting health and disease that can be 
objectively measured, preferably in a minimally-invasive manner. There is an unmet clinical 
need for biomarkers of chronic inflammatory lung diseases that can provide earlier detection, 
ensure optimum treatment and refine prognosis. A common problem is that affected tissue is 
not easily accessible.  Therefore specific, inexpensive biomarkers must be identified that are 
accessible using non-invasive protocols. Extracellular ncRNA in biofluids may represent 
suitable biomarkers for many diseases. In blood, over 100 miRNAs are normally detectable. 
Their presence is thought due to both passive and active mechanisms, including release from 
damaged cells and secretion. miRNAs are particularly attractive as biomarkers because of 
their stability in biofluids, resistance against freeze-thaw and pH, tissue-specific expression, 
conserved sequences, and roles in many human diseases. In cancer and other diseases, 
biofluid miRNAs display particular specificity and sensitivity as biomarkers. Many lncRNAs 
also have the characteristics required for a good biomarker.  
 
 
6. Pre-analytical considerations for ncRNA profiling 
6.1 Tissue versus circulating RNA 
RNA can be easily extracted from lung tissue such as biopsy or brushings and also exists in 
relatively high concentrations in broncho-alveolar lavage fluid (BALF) 78. BALF ncRNA 
analyses have proven valuable in the study of lung disease 79–81. However as described 
earlier, biomarkers should be easily accessible using non-invasive methods. Therefore, there 
is a need for the discovery of biomarkers from fluids such as blood, saliva/sputum and urine. 
Although relatively high concentrations of RNA can be found in saliva/sputum, lower 
concentrations are found in blood and these are lower still in urine (Table 1). Also, before 
embarking upon a lung disease biomarker study one must consider the appropriate source, 
and whether cell-free RNA is required. For instance, although high relative concentrations of 
RNA exist in BALF and sputum, much of this is derived from the lysis of cells during the 
extraction procedure, and not cell-free RNA. This is also the case for urine, where cellular 
RNA contributes greatly to the total RNA found in urine. Given the difficulties in obtaining 
and preparing sputum for isolation of RNA, especially from children or those with low lung 
function 82, and the low RNA concentration in urine, circulating RNA is perhaps the most 
promising candidate for biomarker discovery. ncRNAs present in blood also have potential, 
given that these may be minimally invasive biomarkers of a range of lung diseases. When 
using blood one must first decide empirically whether serum or plasma should be used. 
Although the RNA profile of serum and plasma is generally similar, significant differences 
have been shown 83. The primary difference between serum and plasma is the absence or 
presence, respectively, of fibrinogen and clotting factors 61. Plasma is the supernatant 
obtained after centrifugation of blood which has been collected in the presence of an 
anticoagulant. It is routinely collected in various tubes containing anticoagulants such as 
EDTA, sodium citrate and heparin. However, the selection of anticoagulant containing tubes 
must be carefully considered when examining ncRNA levels as some of these anticoagulants 
inhibit enzymes required for reverse transcription and PCR 84–86. For example, citrate and 
heparin have inhibitory effects on RT-PCR, and therefore EDTA should be used. This also 
appears to be the case with RNA-seq, as heparin has been shown to inhibit reverse 
transcription and the effect of citrate is as of yet unknown.  
Consideration must be given to other factors that can contribute to RNA quantification. The 
timing of food intake prior to sample collection should be recorded and consistency should be 
 
 
maintained across sampling as regards time of day. For instance, high levels of lipoproteins 
can affect RNA extraction efficiency 87. Phlebotomy variables can also affect miRNA and 
lncRNA quantification, generally through affecting lysis of erythrocytes (and possibly 
leukocytes) and activation of platelets by using small gauge needles 88, as these cellular 
components can contribute to and skew the ncRNA profile of samples. Additionally, the time 
between sample collection and sample processing should be standardised. Ideally, protocols 
should be consistent in sample acquisition, storage, processing and quality control checks 
(particularly for haemolysis 89) and however these are currently under-reported in the 
literature.  
Furthermore, if the aim of the study is the identification of circulating miRNA profiles 
specifically, one must bear in mind that miRNA may be transported in complex with proteins 
such as argonaute-2 90; lipoproteins 91; or cellular fragments such as extracellular vesicles and 
exosomes 92,93 and this must be considered when extracting RNA. The most common 
approach to RNA isolation from cell lines or tissue is the use of phenol:chloroform extraction 
and most current techniques are based on this approach. A difficulty in RNA isolation from 
fluids such as serum and plasma is the fact that these highly aqueous samples have very high 
concentrations of protein and extraction therefore involves the scaling up of the lysis reagent 
to specimen ratio several fold 61,87. Several other products are also available for RNA 
isolation from biofluids, with many combining phenol:chloroform extraction with an 
additional silica column-based RNA purification step, which may be particularly useful in 
removing PCR inhibitors. Alternatively, RNA may be separated based on size using 
polyacrylamide gel electrophoresis, and this step is particularly useful in the generation of 
appropriate cDNA libraries for RNA-seq. Finally, once the desired RNA has been obtained, 
its quality must be assessed. Spectrophotometric measurements are simple and cheap 
methods for determination of RNA concentration and quality control e.g. evaluation of 
phenol and protein contamination. However, these QC measures suffer from low sensitivity 94 
and are not particularly useful with samples of low RNA concentration. Electrophoretic 
analysis of RNA integrity is useful and automated capillary electrophoresis instruments are 
widely available, such as the Agilent Bioanalyzer and the Bio-Rad Experion; but these are 
significantly more expensive as compared to spectrophotometric methods. Finally, as alluded 
to earlier, spike-in of synthetic RNAs can be useful in determining RNA extraction 
efficiency.  
 
 
 
7. Expert commentary 
With the current enthusiasm within the field of ncRNA, our understanding of the epigenetic 
arena is increasing. However, as we discover more detail about ncRNAs, how they function 
and their roles in health and disease, we realise that we are only at the very beginning of this 
process. Much more work is required to truly understand their roles, especially in the context 
of human disease. Nonetheless, we can benefit from the functional or epiphenomenal 
presence of these molecules in biofluids without necessarily knowing their exact functions. 
Certain characteristics of ncRNA, circulating or otherwise, underscore their potential use as 
diagnostic or prognostic non-invasive biomarkers of human disease, or response to therapy. 
With this in mind, their use as biomarkers deserves fuller interrogation, as current biomarkers 
of lung disease in particular are lacking. In order to do this, improvements in high throughput 
discovery and profiling technologies must be married with a simultaneous improvement in 
computational methodologies, to better identify true ncRNA biomarkers. Careful 
consideration must be taken with respect to the design of biomarker discovery and validation 
studies; from sampling to processing through to profiling, validation and clinical 
interpretation. Key aspects driving these studies must be accuracy, reliability and 
reproducibility. Great care must be taken in developing optimized methods for miRNA 
extraction, analysis and detection and it will be important that researchers in the field reach 
consensus on detection methods. International efforts should be undertaken via task forces or 
research networks to develop standard operating procedures to optimize biofluid processing, 
ensure quality control and include standardisation of assays. Beyond that extensive validation 
studies will need to be carried out in geographically distinct cohorts to truly determine the 
diagnostic/prognostic potential of any individual ncRNA panel.  
 
8. Five-year view 
Emphasis is ever-increasingly being placed on the study of non-coding RNAs by the 
scientific community at large, with an explosion in the number of studies and data produced 
pertaining to these intriguing biomolecules in the last few years. Their involvement in human 
disease has become increasingly apparent, and their use as biomarkers of disease is 
increasingly being investigated. Although up until now miRNAs have been extensively 
investigated, focus is increasing on other ncRNAs; and in particular long non-coding RNAs. 
The presence of miRNAs and lncRNAs in body fluids and in particular in blood means that 
 
 
these have extremely high potential as clinical markers of lung disease, as diagnostic and/or 
prognostic tools, and also as predictors for assessing response to therapy. In fact, some 
diagnostic tests employing ncRNA are already commercially available13,95–97, with many 
others expected to follow.  
 
Most research to date on miRNA as biomarkers has focused on blood as a source 
(serum/plasma). This of course has advantages in terms of providing sufficient RNA. 
However, the risk of haemolysis and other cell-derived contaminants requires stringent 
quality controls. Additionally, the requirement for venepuncture can be limiting particular 
where repeated sampling is needed, where out-of-hospital care might require use of blood-
based ncRNA biomarker profiling, and particularly with vulnerable groups such as children 
and infants. There is, therefore, significant interest and opportunity in exploring other 
biofluid sources for miRNA biomarkers.  
 
More effort is required to evaluate novel sources of ncRNA biomarkers e.g. saliva, urine, that 
are more accessible from young patients and potentially more cost effective. Thus it is 
essential that we (1) develop optimized techniques for miRNA and lncRNA profiling of 
novel biofluids, (2) study normal variation and stability of ncRNA in these biofluids in 
relation to standards (e.g. plasma); and (3) assess the potential of these novel biofluid sources 
for future potential microfluidic diagnostic point-of-care/lab-on-a-chip devices.  
 
Other challenges yet to be fully explored and discussed in a transdisciplinary manner are the 
most appropriate and robust biostatistical and bioinformatics methodologies to apply when 
analysing ncRNA data (e.g. normalisation, correlative statistics). Given the global interest in 
ncRNA biomarkers in lung disease and beyond, it is highly likely that the number of 
approved clinical biomarker tests and standardised methods for ncRNA biomarker 
quantification will be developed in the near future.  
 
 
  
 
 
9. Key Issues 
 
 miRNA and lncRNA expression is altered in COPD, asthma, CF and IPF. These non-
coding RNAs are detectable in various biofluids and are potential clinical biomarkers 
for diagnosis, prognosis and assessment of response to therapy. 
 The major high throughput approaches for profiling of non-coding RNA are 
hybridisation (microarrays), qRT-PCR and RNA sequencing (RNA-seq/NGS). Each 
method has its own benefits and limitations which can affect the choice of method 
when embarking on a biomarker study. 
 qRT-PCR is the easiest and most widely used method for detection of non-coding 
RNA, with high-throughput analysis of lncRNA expression by qRT-PCR lagging 
behind that of miRNA. qRT-PCR remains the ‘gold-standard’ in expression studies 
and is useful in the validation of high-throughput data. 
 Microarrays are reproducible, flexible and can simultaneously detect a large number 
of non-coding RNAs. Although cost effective, their limitations include a narrow 
linear range of quantification, imperfect sensitivity for highly similar miRNA 
sequences, and they cannot be used for absolute quantification. 
 The major advantage of RNA-seq is that prior knowledge of target non-coding RNA 
is not required, nor are specific primers or probes needed. RNA-seq has a large 
dynamic range and can detect transcripts with very low expression, however the 
method is expensive. 
 Data normalisation is essential to remove variation between samples not due to 
biological conditions and can be difficult for samples with low RNA concentrations 
such as serum/plasma. The two most common normalisation methods for large-scale 
qRT-PCR and microarray profiling are the use of reliable endogenous control RNAs 
or global normalisation utilising the entire dataset.  
 Various biospecimens can be used for lung biomarker studies including whole blood, 
serum, plasma, peripheral blood cells, bronchoalveolar lavage fluid, bronchial 
brushings, sputum, exhaled breath condensates or urine. Ideally biomarkers should be 
easily accessible using non-invasive methods. Each biofluid has characteristics that 
can affect non-coding RNA detection. 
 Accuracy, reliability and reproducibility of the methodologies are tantamount within 
this field. Current emphasis should focus on developing standard operating 
 
 
procedures and standardisation of assays coupled with the most appropriate and 
robust data interpretation approaches. 
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